Recent Research Analysts’ Ratings Updates for Valeant Pharmaceuticals Intl (VRX)

Valeant Pharmaceuticals Intl (NYSE: VRX) has recently received a number of price target changes and ratings updates:

  • 1/19/2018 – Valeant Pharmaceuticals Intl was given a new $25.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock. They wrote, “There has been some concern that VRX’s Xifaxan could face competition from Cosmo Pharmaceuticals (Not Covered) as early as 2019. We reiterate our Overweight rating and price target of $25; we don’t see fundamental reasons for the stock’s weakness this morning.””
  • 1/16/2018 – Valeant Pharmaceuticals Intl had its “sell” rating reaffirmed by analysts at Wells Fargo & Co. They now have a $9.00 price target on the stock.
  • 1/16/2018 – Valeant Pharmaceuticals Intl had its price target raised by analysts at HC Wainwright from $17.00 to $24.00. They now have a “buy” rating on the stock.
  • 1/16/2018 – Valeant Pharmaceuticals Intl was given a new $24.00 price target on by analysts at HC Wainwright. They now have a “hold” rating on the stock.
  • 1/13/2018 – Valeant Pharmaceuticals Intl was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “strong sell” rating. According to Zacks, “After a tumultuous period, Valeant started a rebuilding process with its CEO, Joseph C. Papa. Even though it is still early to comment on the rebuilding process, but the company’s efforts to sell non-core assets and pay down huge levels of debt is commendable and should bode well in the upcoming quarters. The company is also divesting Sprout Pharmaceuticals and ADDYI businesses. The weakness in the dermatology business was also a cause of concern given Valeant's dependence on the same. Although third-quarter 2017 results were encouraging, the company trimmed its guidance due to recent divestitures. Shares of the company have outperformed the industry in the last six months. However, we believe this might just not be enough to boost sentiment. “
  • 1/5/2018 – Valeant Pharmaceuticals Intl had its price target raised by analysts at TD Securities from $20.00 to $27.00. They now have a “buy” rating on the stock.
  • 1/4/2018 – Valeant Pharmaceuticals Intl had its “sell” rating reaffirmed by analysts at Wells Fargo & Co.
  • 1/1/2018 – Valeant Pharmaceuticals Intl was given a new $25.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 12/26/2017 – Valeant Pharmaceuticals Intl was given a new $25.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 12/15/2017 – Valeant Pharmaceuticals Intl had its price target raised by analysts at Mizuho from $7.00 to $10.00. They now have an “underperform” rating on the stock.
  • 12/14/2017 – Valeant Pharmaceuticals Intl was downgraded by analysts at JPMorgan Chase & Co. from a “neutral” rating to an “underweight” rating. They now have a $12.00 price target on the stock.
  • 12/12/2017 – Valeant Pharmaceuticals Intl was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 12/5/2017 – Valeant Pharmaceuticals Intl was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $19.72 price target on the stock.
  • 12/4/2017 – Valeant Pharmaceuticals Intl was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating. They now have a $19.18 price target on the stock.
  • 12/3/2017 – Valeant Pharmaceuticals Intl was given a new $18.00 price target on by analysts at Deutsche Bank AG. They now have a “hold” rating on the stock.

Valeant Pharmaceuticals Intl Inc (NYSE VRX) traded down $0.58 on Monday, hitting $21.52. 15,382,400 shares of the company traded hands, compared to its average volume of 14,526,377. The company has a debt-to-equity ratio of 4.84, a quick ratio of 1.03 and a current ratio of 1.26. Valeant Pharmaceuticals Intl Inc has a 1 year low of $8.31 and a 1 year high of $24.43. The firm has a market cap of $7,690.00, a PE ratio of 5.52, a P/E/G ratio of 0.65 and a beta of -0.22.

Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX) last posted its earnings results on Tuesday, November 7th. The specialty pharmaceutical company reported $1.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.90 by $0.14. Valeant Pharmaceuticals Intl had a net margin of 15.35% and a return on equity of 51.56%. analysts forecast that Valeant Pharmaceuticals Intl Inc will post 3.82 earnings per share for the current fiscal year.

In other news, Director John Paulson bought 344,216 shares of the firm’s stock in a transaction that occurred on Thursday, November 16th. The stock was purchased at an average cost of $14.40 per share, for a total transaction of $4,956,710.40. Following the purchase, the director now directly owns 94,559 shares in the company, valued at approximately $1,361,649.60. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 5.87% of the company’s stock.

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Receive News & Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply